Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Antagonism of IAPs Enhances CAR T-cell Efficacy.

Michie J, Beavis PA, Freeman AJ, Vervoort SJ, Ramsbottom KM, Narasimhan V, Lelliott EJ, Lalaoui N, Ramsay RG, Johnstone RW, Silke J, Darcy PK, Voskoboinik I, Kearney CJ, Oliaro J.

Cancer Immunol Res. 2019 Feb;7(2):183-192. doi: 10.1158/2326-6066.CIR-18-0428. Epub 2019 Jan 16.

PMID:
30651288
2.

PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.

Kearney CJ, Lalaoui N, Freeman AJ, Ramsbottom KM, Silke J, Oliaro J.

Cell Death Differ. 2017 Oct;24(10):1705-1716. doi: 10.1038/cdd.2017.94. Epub 2017 Jun 30.

3.

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.

PMID:
23225169
4.

Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK.

Mol Cancer Ther. 2014 Apr;13(4):867-79. doi: 10.1158/1535-7163.MCT-13-0798. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2246-7. Dosage error in article text.

5.

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.

Mol Cancer Ther. 2015 Nov;14(11):2569-75. doi: 10.1158/1535-7163.MCT-15-0475. Epub 2015 Sep 2.

6.

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, Carol H, Heatley S, Sutton R, Marshall GM, White D, Pimanda J, Houghton PJ, Smith MA, Lock RB.

Cancer Res. 2016 Aug 1;76(15):4579-91. doi: 10.1158/0008-5472.CAN-16-0523. Epub 2016 Jun 14.

7.

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Wang Z, Guo Y, Han W.

Protein Cell. 2017 Dec;8(12):896-925. doi: 10.1007/s13238-017-0400-z. Epub 2017 May 2. Review.

8.

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma.

Chen Z, Chen J, Liu H, Dong W, Huang X, Yang D, Hou J, Zhang X.

Front Pharmacol. 2018 Nov 6;9:1298. doi: 10.3389/fphar.2018.01298. eCollection 2018.

9.

The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J.

Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. Erratum in: Sci Transl Med. 2017 May 31;9(392):.

PMID:
27194727
10.

Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.

Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD, Ojaimi S, Baschuk N, Nachbur U, Torresi J, Silke J, Begley CG, Pellegrini M.

Proc Natl Acad Sci U S A. 2015 May 5;112(18):5803-8. doi: 10.1073/pnas.1502400112. Epub 2015 Apr 20.

11.

Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.

McComb S, Aguadé-Gorgorió J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stanulla M, von Stackelberg A, Bourquin JP, Bornhauser BC.

Sci Transl Med. 2016 May 18;8(339):339ra70. doi: 10.1126/scitranslmed.aad2986.

PMID:
27194728
12.

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.

Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M.

Acta Pharm Sin B. 2018 Jul;8(4):539-551. doi: 10.1016/j.apsb.2018.03.001. Epub 2018 Apr 5. Review.

13.

Design of small-molecule peptidic and nonpeptidic Smac mimetics.

Sun H, Nikolovska-Coleska Z, Yang CY, Qian D, Lu J, Qiu S, Bai L, Peng Y, Cai Q, Wang S.

Acc Chem Res. 2008 Oct;41(10):1264-77. doi: 10.1021/ar8000553.

14.

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. Review.

15.

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, Nilsson K, Frisk P, Jernberg-Wiklund H, Loskog A.

Cancer Gene Ther. 2013 Jul;20(7):386-93. doi: 10.1038/cgt.2013.35. Epub 2013 Jun 21. Erratum in: Cancer Gene Ther. 2013 Dec;20(12):702. Karlsson, S C H [corrected to Karlsson, H];Loskog, S I A [corrected to Loskog, A].

PMID:
23788110
16.

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Xia AL, Wang XC, Lu YJ, Lu XJ, Sun B.

Oncotarget. 2017 Jul 18;8(52):90521-90531. doi: 10.18632/oncotarget.19361. eCollection 2017 Oct 27. Review.

17.

The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.

Liu H, Liao R, He K, Zhu X, Li P, Gong J.

Immunol Lett. 2017 May;185:79-83. doi: 10.1016/j.imlet.2017.02.016. Epub 2017 Mar 9.

PMID:
28286228
18.

Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW.

Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Review.

PMID:
29861325
19.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

20.

Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ.

Mol Ther. 2015 Apr;23(4):769-78. doi: 10.1038/mt.2015.4. Epub 2015 Jan 13.

Supplemental Content

Support Center